What does CUSIP 114082209 represent in this 13F holders report?

CUSIP 114082209 is the security identifier for ERNA - Ernexa Therapeutics Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held ERNA - Ernexa Therapeutics Inc. - Common Stock in Q2 2023?

19 institutional investors reported ERNA - Ernexa Therapeutics Inc. - Common Stock for Q2 2023. Use the holders table for investor-level position and value details.

Ernexa Therapeutics Inc. - Common Stock (ERNA)

CUSIP: 114082209

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class: Equity / Common Stock
Shares outstanding: 1,166,181
Total 13F shares: 333,250
Share change: +1,452
Total reported value: $750,186
Price per share: $2.26
Number of holders: 19
Value change: -$15,587
Number of buys: 6
Number of sells: 6

Security key

114082209

Report period

Q2 2023

Institutions

Top holders

ERNA full security history Newer quarter: Q3 2023 Previous quarter: Q1 2023 Ernexa Therapeutics Inc. SEC filings Ernexa Therapeutics Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 114082209

Newer quarter: Q3 2023 Previous quarter: Q1 2023

Recent filing periods:

Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023

Top shareholders of ERNA - Ernexa Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Cypress Point Wealth Management, LLC	13F	Company	8.1%	94,375	$320,875	—	31 Mar 2023	13F
Naviter Wealth, LLC	13F	Company	6.8%	79,666	$270,864	—	31 Mar 2023	13F
Corient Private Wealth LLC	13F	Company	5.2%	61,189	$214,071	—	31 Mar 2023	13F
BlackRock Finance, Inc.	13F	Company	2%	23,363	$79,434	—	31 Mar 2023	13F
VANGUARD GROUP INC	13F	Company	1.6%	19,068	$64,831	—	31 Mar 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.2%	13,985	$48,947	—	31 Mar 2023	13F
Sippican Capital Advisors	13F	Company	1.2%	13,500	$45,900	—	31 Mar 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	1.1%	13,053	$44,000	—	31 Mar 2023	13F
BALDWIN WEALTH PARTNERS LLC/MA	13F	Company	0.81%	9,470	$32,198	—	31 Mar 2023	13F
UBS Group AG	13F	Company	0.33%	3,864	$13,138	—	31 Mar 2023	13F
Carmichael Hill & Associates, Inc.	13F	Company	0.01%	75	$255	—	31 Mar 2023	13F
MONTAG A & ASSOCIATES INC	13F	Company	0.01%	70	$238	—	31 Mar 2023	13F
MORGAN STANLEY	13F	Company	0%	50	$170	—	31 Mar 2023	13F
GROUP ONE TRADING LLC	13F	Company	0%	19	$67	—	31 Mar 2023	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	16	$54	—	31 Mar 2023	13F
CITIGROUP INC	13F	Company	0%	15	$53	—	31 Mar 2023	13F
Aspire Private Capital, LLC	13F	Company	0%	10	$34	—	31 Mar 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	9	$31	—	31 Mar 2023	13F
FMR LLC	13F	Company	0%	1	$4	—	31 Mar 2023	13F
George P. Denny III	3/4/5	10%+ Owner	— class O/S missing	457,442	$1,134,456	—	02 Dec 2022	3/4/5
John D. Halpern	3/4/5	10%+ Owner	— mixed-class rows	1,123,006 mixed-class rows	$1,118,891	—	02 Dec 2022	3/4/5
Nicholas J. Singer	3/4/5	Director	— mixed-class rows	954,608 mixed-class rows	$962,330	—	02 Dec 2022	3/4/5
Roger Sidhu	3/4/5	Chief Medical Officer	— mixed-class rows	80,650 mixed-class rows	$200,012	—	20 Sep 2022	3/4/5
Kevin Damour	3/4/5	Chief Scientific Officer	— mixed-class rows	64,213 mixed-class rows	$159,248	—	28 Jun 2022	3/4/5
Andrew C. Jackson	3/4/5	Chief Financial Officer	— class O/S missing	664,800	—	—	03 Jun 2022	3/4/5
Howard J. Federoff	3/4/5	CEO & President, Director	— class O/S missing	413,700	—	—	11 Mar 2022	3/4/5
Gregory Fiore	3/4/5	Director	— class O/S missing	165,800	—	—	01 Aug 2022	3/4/5
Matthew Angel	3/4/5	President and CEO, Director	— class O/S missing	132,003	—	—	12 Jan 2023	3/4/5
Jay Sial	3/4/5	Chief Administration Officer	— class O/S missing	117,200	—	—	11 Mar 2022	3/4/5
Dennis Langer	3/4/5	Director	— class O/S missing	67,000	—	—	08 Dec 2021	3/4/5
Erich Mohr	3/4/5	Director	— class O/S missing	67,000	—	—	08 Dec 2021	3/4/5
Erin S. Enright	3/4/5	Director	— class O/S missing	67,000	—	—	14 Jan 2022	3/4/5
Heather B. Redman	3/4/5	Director	— class O/S missing	67,000	—	—	14 Jan 2022	3/4/5
Luba Greenwood	3/4/5	Director	— class O/S missing	67,000	—	—	08 Dec 2021	3/4/5

Institutional Holders of Ernexa Therapeutics Inc. - Common Stock (ERNA) as of Q2 2023

As of 30 Jun 2023, Ernexa Therapeutics Inc. - Common Stock (ERNA) was held by 19 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 333,250 shares. The largest 10 holders included Cypress Point Wealth Management, LLC, Naviter Wealth, LLC, Corient Private Wealth LLC, Sippican Capital Advisors, VANGUARD GROUP INC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, GOLDMAN SACHS GROUP INC, BALDWIN BROTHERS LLC/MA, and Tower Research Capital LLC (TRC). This page lists 19 institutional shareholders reporting positions in this security for the Q2 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Q2 2023 holders

Holder diff

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 Value $	Q2 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.